Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 281

Results For "RAT"

8419 News Found

HRV Global Life Sciences delivers Indian anti-diabetic drugs to Argentina
News | April 01, 2025

HRV Global Life Sciences delivers Indian anti-diabetic drugs to Argentina

The consignment of USFDA qualified Metformin (1000mg) was received by the province of Mendoza for distribution in the public health system


GE HealthCare launches new advanced CT system
News | April 01, 2025

GE HealthCare launches new advanced CT system

GE HealthCare’s Revolution Vibe CT enables more facilities to elevate patient care by offering advanced cardiac imaging technology


Briefs: AstraZeneca Pharma India, Pharmaids and Dr. Agarwal's Health Care
News | April 01, 2025

Briefs: AstraZeneca Pharma India, Pharmaids and Dr. Agarwal's Health Care

AstraZeneca Pharma India discontinues manufacturing of Imdur


NCLT approves amalgamation of Cohance Lifesciences into and with Suven Pharmaceuticals
News | April 01, 2025

NCLT approves amalgamation of Cohance Lifesciences into and with Suven Pharmaceuticals

The amalgamation is expected to create a future-ready, diversified CDMO platform with a technology-led focus across three high-growth verticals-Antibody Drug Conjugates


Akums launches Ripasudil + Timolol combination for glaucoma treatment
News | April 01, 2025

Akums launches Ripasudil + Timolol combination for glaucoma treatment

The new combination therapy offers a dual mechanism of action for superior intraocular pressure control


OneSource Specialty Pharma updates on cGMP inspection by USFDA
Drug Approval | April 01, 2025

OneSource Specialty Pharma updates on cGMP inspection by USFDA

The inspection has concluded with four observations


DKSH Technology acquires Korean life science firm MDxK
Supply Chain | March 31, 2025

DKSH Technology acquires Korean life science firm MDxK

The acquisition of MDxK further strengthens the Business Unit’s position in the molecular diagnostics market


Merck seeks FDA approval for subcutaneous pembrolizumab
Drug Approval | March 29, 2025

Merck seeks FDA approval for subcutaneous pembrolizumab

Subcutaneous pembrolizumab administered every six weeks with a median injection time of two minutes, in combination with chemotherapy, shows consistent results across reported efficacy and safety endpoints compared to IV KEYTRUDA in combination with chemotherapy


Curium completes acquisition of Monrol
News | March 29, 2025

Curium completes acquisition of Monrol

Positions Curium as leading manufacturer of Lu-177 isotope


Novo Nordisk strikes $1bn deal for Lexicon’s oral obesity drug
News | March 29, 2025

Novo Nordisk strikes $1bn deal for Lexicon’s oral obesity drug

Lexicon Pharmaceuticals announces exclusive license agreement with Novo Nordisk for LX9851